Independent academic projectNot an official Nemaura Medical website
NEMAURACOMPANY RESEARCH PROFILEContact Us
Menu

What We Do · Product ecosystem

Wearable sensing meets digital health.

The company’s work spans a non-invasive glucose sensor, AI-supported lifestyle programs, clinical pilots and partnership-led commercialization.

sugarBEAT®+proBEAT™+BEAT®

CAPABILITIES

One platform. Several applications.

Nemaura’s reported activities can be grouped into four connected areas.

01
⌁

Wearable diagnostics

Developing flexible skin-worn sensors designed to obtain frequent glucose measurements without an inserted needle.

Explore technology ↗
02
◎

Digital coaching

Combining glucose trends with AI-supported feedback, education and subscription-based lifestyle programs.

See programs ↓
03
◇

Clinical programs

Using pilots and studies to assess metabolic health, diabetes management and potential hospital applications.

Review evidence ↗
04
↗

Partnerships & licensing

Working with licensees, distributors, employers and health-service partners to explore market entry and scale.

Business context ↗

PRODUCTS & PROGRAMS

The reported portfolio.

01 / MEDICAL DEVICE

sugarBEAT®

Daily-wear adhesive sensor patch, rechargeable transmitter and mobile application for glucose trend monitoring at approximately five-minute intervals.

CE Mark · Class IIb
02 / WELLNESS PLATFORM

proBEAT™

A wellness-oriented use of non-invasive glucose data with AI-supported guidance, digital healthcare and subscription services.

U.S. pilots reported
03 / COACHING PROGRAM

BEAT® diabetes

Lifestyle, weight-management and diabetes-support programming built around sensor-derived information.

Digital health
04 / METABOLIC HEALTH

Miboko

A reported beta program intended to relate food and lifestyle habits to metabolic-health patterns.

Exploratory

COMMERCIALIZATION EVIDENCE

Activity has been visible; scale remains limited.

Orders, expressions of interest and pilots should be distinguished from completed sales and sustained adoption.

UK & Ireland

An exclusive marketing arrangement and later launch planning covered the United Kingdom, Republic of Ireland, Channel Islands and Isle of Man.

United States

Digital-health pilots and a reported HealthFleet relationship formed part of the U.S. commercialization approach.

Scaling challenge

Licensee relationships, provisional orders, hospital exploration and commercial interest demonstrate activity—not broad, repeatable product revenue.

HOW THE MODEL WORKS

Develop, validate, partner, scale.

01

Develop

Sensor chemistry, patch design, transmitter hardware and mobile experiences.

02

Validate

Clinical studies, usability work and jurisdiction-specific regulatory processes.

03

Partner

Licensees, distributors, employers, insurers and health-program collaborators.

04

Scale

Contract manufacturing and market-by-market commercialization.

Independent educational project

This website is not affiliated with Nemaura Medical Inc. and does not provide medical or investment advice.